Holen Sie sich die Stockscreener-App
6.11
0.66%
0.04
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
Understanding Momentum Shifts in (CVRX) - Stock Traders Daily
CVRx, Inc.Common Stock (NQ: CVRX - The Chronicle-Journal
Clinical research teams accelerate progress in treatment options, CVRx asserts - Traders Union
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders - simplywall.st
CVRx to present at William Blair Growth Stock Conference on June 2, 2026 - Pluang
CVRx to Present at the William Blair 46th Annual Growth Stock Conference - The Manila Times
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill - Traders Union
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy - Yahoo Finance
CVRx rebounds as Humana issues Medicare policy for Barostim - MSN
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight - AD HOC NEWS
Number of shareholders of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRx Gains Momentum With Revenue Growth, BENEFIT-HF Progress and Humana Coverage Win - TipRanks
CVRx (CVRX) reports Q1 loss, beats revenue estimates - MSN
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report - Yahoo Finance
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy - Sahm
Humana (HUM) Expands Medicare Advantage Coverage for Barostim Th - GuruFocus
CVRx earns Humana Medicare Advantage win for Barostim - MassDevice
CVRx stock gains as Humana to cover Barostim - Seeking Alpha
Humana issues Medicare Advantage coverage for CVRx Barostim therapy By Investing.com - Investing.com Nigeria
Humana issues Medicare Advantage coverage for CVRx Barostim therapy - Investing.com
Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal - Traders Union
CVRx announces Humana Medicare Advantage coverage policy for Barostim therapy - marketscreener.com
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
CVRx Inc | 10-Q: Q1 2026 Earnings Report - Moomoo
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - Yahoo Finance
TradingKey - TradingKey
CVRx Earnings Call Highlights Growth Amid Ongoing Losses - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CVRx stock (US12674F1003): Q1 revenue jumps 20% to $14.8M - AD HOC NEWS
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - Moomoo
J.P. Morgan Maintains CVRx Inc(CVRX.US) With Sell Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for CVRx Inc(CVRX.US), With a Forecast Between $6 to $12 - Moomoo
CVRx, Inc. (NASDAQ:CVRX) Q1 2026 Earnings Call Transcript - Insider Monkey
CVRx revenue up 20% to USD 14.8M in Q1 2026 - Medical Buyer
CVRx, Inc. 1Q 2026: Revenue $14.77M, EPS ($0.5) — 10-Q Summary - TradingView
CVRx (NASDAQ: CVRX) grows Q1 revenue 20% as net loss narrows - Stock Titan
Avoiding Lag: Real-Time Signals in (CVRX) Movement - Stock Traders Daily
CVRx earnings beat by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Australia
CVRx Q1 Earnings Call Highlights - sharewise.com
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises - Investing.com India
CVRx revenue rises 20 percent in first quarter as U.S. operations expand - Traders Union
CVRX: Q1 2026 delivered strong revenue growth, margin expansion, and strategic progress in U.S. heart failure therapy - TradingView
CVRx (CVRX) Q1 2026 Earnings Call Transcript - AOL.com
CVRX: Q1 2026 revenue grew 20% with strong U.S. performance and improved gross margin - TradingView
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
0.22%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):